Recent advances in genomic technology have led to a better understanding of key
molecular alterations that underlie glioblastoma (GBM). The current WHO-based …

Glioblastoma is the most frequent and malignant brain tumor. The vast majority of
glioblastomas (∼ 90%) develop rapidly de novo in elderly patients, without clinical or …

Purpose Mutation in isocitrate dehydrogenase 1 (IDH1) at R132 (IDH1 R132MUT) is
frequent in low-grade diffuse gliomas and, within glioblastoma (GBM), has been proposed …

To identify novel glioma‐associated pathomechanisms and molecular markers, we
performed an array‐based comparative genomic hybridization analysis of 131 diffuse …

While the classification of diffuse gliomas has relied on the examination of morphologic
features supplemented with techniques such as immunohistochemistry, there is an …

Glioblastoma is the most fatal brain cancer found in humans. Patients suffering from
glioblastoma have a dismal prognosis, with a median survival of 15 months. The tumor may …

This article reviews the histologic and molecular characterization of gliomas, including the
new “integrated diagnoses” of the World Health Organization Classification, 2016 edition …

Diffuse gliomas are among the most common adult central nervous system tumors with an
annual incidence of more than 16,000 cases in the United States. Until very recently, the …

Gliomas are a large and diverse group of primary brain tumors that include those that are
diffusely infiltrative and others that are well-circumscribed and low grade. Diffuse gliomas …

One of the most vexing issues in diagnostic neuropathology relates to the distinction of
diffuse astrocytomas (and other diffuse gliomas) from astrocytosis (gliosis) on biopsies …